Trulieve Cannabis Corp. (NYSE: TRLV) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Trulieve Cannabis Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.07, Trulieve Cannabis Corp. trades at 1.6x sales and 2.5x book value. Over the last twelve months it generated about $1.1B of revenue and a net loss of $394M. It runs a gross margin of 60.6%, an operating margin of -25.3% and a net margin of -41.2%. It shows return on equity of -46.1%, return on invested capital of -13.4% and a free cash flow yield of 10.0%. On the balance sheet: a debt-to-equity ratio of 0.60 and a current ratio of 5.52. Over the past 52 weeks the share price ranged from $4.62 to $13.28, with a beta of 1.92.
Trulieve Cannabis Corp. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.